Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25313131 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AGRIN2BDRD2 | |
| SCHEMBL29386221 | 0.94 | DRD2 (0.48) | SMN1; SMN2NPC1RAB9AGRIN2BDRD2 | |
| SCHEMBL28978040 | 0.90 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AGRIN2BHTT | |
| SCHEMBL951538 | 0.90 | KMT2A (0.59) | SMN1; SMN2NPC1RAB9AGRIN2BHTT | |
| SCHEMBL31251067 | 0.89 | DRD2 (0.47) | SMN1; SMN2NPC1RAB9AGRIN2BDRD2 | |
| SCHEMBL22835959 | 0.87 | KMT2A (0.51) | SMN1; SMN2NPC1RAB9AGRIN2BHTT | |
| SCHEMBL27224954 | 0.86 | DRD2 (0.59) | SMN1; SMN2NPC1RAB9ADRD2HTT | |
| SCHEMBL27039636 | 0.86 | DRD2 (0.49) | SMN1; SMN2NPC1RAB9AGRIN2BDRD2 | |
| SCHEMBL6580050 | 0.86 | DRD2 (0.54) | SMN1; SMN2NPC1RAB9AGRIN2BDRD2 | |
| SCHEMBL27039446 | 0.85 | DRD2 (0.48) | SMN1; SMN2NPC1RAB9AGRIN2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | SMN1; SMN2 3854/4885NPC1 2315/4885RAB9A 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.